Black Diamond Therapeutics Inc
$ 1.76
-4.35%
24 Jul - close price
- Market Cap 105,435,000 USD
- Current Price $ 1.76
- High / Low $ 1.83 / 1.75
- Stock P/E N/A
- Book Value 1.82
- EPS -0.77
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.35 %
- 52 Week High 4.94
- 52 Week Low 1.60
About
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$9.86
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-16 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-06 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-06 | 2023-08-11 |
| Reported EPS | -0.16 | -0.1361 | -0.15 | -0.19 | 0.98 | -0.28 | -0.2753 | -0.36 | -0.35 | -0.34 | -0.45 | -0.52 |
| Estimated EPS | -0.0294 | -0.1746 | -0.235 | -0.25 | -0.255 | -0.3117 | -0.37 | -0.39 | -0.43 | -0.47 | -0.49 | -0.54 |
| Surprise | -0.1306 | 0.0385 | 0.085 | 0.06 | 1.235 | 0.0317 | 0.0947 | 0.03 | 0.08 | 0.13 | 0.04 | 0.02 |
| Surprise Percentage | -444.2177% | 22.0504% | 36.1702% | 24% | 484.3137% | 10.17% | 25.5946% | 7.6923% | 18.6047% | 27.6596% | 8.1633% | 3.7037% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDTX
2026-07-13 06:41:43
This article summarizes Black Diamond Therapeutics' 24th Annual Needham Virtual Healthcare Conference, held on December 27, 2025. Key highlights include the development of oral oncology therapies, particularly BDTX-1535 for non-small cell lung cancer (NSCLC) and glioblastoma, with anticipated clinical updates and a cash runway into Q4 2027. The company also discussed positive clinical data for BDTX-1535, its broad activity across different EGFR mutations, and its competitive positioning in addressing unmet needs in NSCLC.
2026-07-08 15:39:17
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I (BDTX) common stock, which represents a 7.0% stake as of June 30, 2026. The filing specifies that T. Rowe Price holds sole voting power over 3,992,774 shares and sole dispositive power over all 4,028,202 shares. Notably, the filing includes a statement explicitly denying that Price Investment Management is the beneficial owner of these securities.
2026-07-04 04:39:55
This article analyzes Black Diamond Therapeutics Inc.'s (BDTX) financial performance, focusing on its profitability and market position. It highlights the company's undefined gross, operating, and net margins, alongside a Return on Equity (ROE) of -35.16%. The analysis also includes a comparison of BDTX with industry competitors CGTX and RANI, noting BDTX's market capitalization of $115.18M.
2026-07-01 23:10:19
This page provides a comprehensive resource for Black Diamond Therapeutics (BDTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms (Form 4). Recent filings highlight director stock compensation in lieu of cash, indicating insider confidence, with specific details on shares issued and beneficial ownership for directors Behbahani Ali and Raman Prakash. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for these regulatory documents, with the most recent filing dated September 22, 2025.
2026-07-01 10:12:12
This article reports a statement of changes in beneficial ownership of securities for Director Behbahani Ali at Black Diamond Therapeutics. This indicates a filing related to insider trading or changes in stock holdings by a company director.
2026-07-01 04:11:23
Black Diamond Therapeutics (NASDAQ: BDTX) is an unprofitable biotech company that has a cash runway of about 3.5 years based on its current cash burn rate of US$34 million per year and cash reserves of US$118 million as of March 2026. While its cash burn represents 34% of its US$100 million market capitalization, potentially leading to dilution if more funds are needed, its long cash runway is a significant positive. The company is in a good position to invest in its growth given its current financial standing.
